EntreChem has built a network of collaborators and key opinion leaders who actively help the company to add value to our drugs.
For the development of new molecules, EntreChem actively collaborates with a number of national and international research groups in order to characterize the Mechanism of Action and identify biomarkers and sensitive tumors.
16
- Carlo Catapano, Ph.D., M.D., Institute for Oncology Research (Bellinzona, Switzerland)
- Pina Carbone, Ph.D., Institute for Oncology Research (Bellinzona, Switzerland)
- Prostate cancer
- Patrick Grohar, Ph.D., M.D., Children’s Hospital of Philadelphia (Pennsylvania, USA)
- Ewing sarcoma
- David Schrump, Ph.D., M.D., NCI (Bethesda, USA)
- Lung cancer
- Atanasio Pandiella, Ph.D., CIC (Salamanca, Spain)
- Triple negative breast cancer and other tumors
- Alberto Ocaña, Ph.D., M.D., Hospital Clínico San Carlos (Madrid, Spain)
- Triple negative breast cancer and other tumors
- Pablo Menéndez, Ph.D., Josep Carreras Leukaemia Research Institute (Barcelona, Spain)
- Leukaemia
- Jesús Paramio, Ph.D., CIEMAT (Madrid, Spain)
- Mario Hermsen, Ph.D., IUOPA (Oviedo, Spain)
- Head&Neck cancer
- Segundo González, Ph.D., M.D. University of Oviedo (Spain)
- Oncoimmunology
- René Rodríguez, Ph.D., IUOPA (Oviedo, Spain)
- Sarcoma
- Jose Luis Fernández-Luna, Ph.D., Hospital Valdecilla (Santander, Spain)
- Carmen Rodríguez, Ph.D., University of Oviedo (Spain)
- Serafín Costilla, Ph.D., M.D., HUCA (Oviedo, Spain)
- Glioblastoma
- José Portugal, Ph.D., IBMB-CSIC (Barcelona, Spain)
- Mithralogs DNA-Binding Mechanisms
- Jurgen Rohr, Ph.D., University of Kentucky (USA)
- Combinatorial biosynthesis